Drug candidates directed against amyloid-β (Aβ) are mainstream in Alzheimer's disease
(AD) drug development. Active and passive Aβ immunotherapy is the principle that has …

Alzheimer's disease (AD) is an incurable neurodegenerative disease and many types of
stem cells have been used in AD therapy with some favorable effects. In this study, we …

OBJECTIVE: The aim of this study was to investigate the role of miR-16 in Alzheimer's
disease (AD) and to explore its mechanism of action. MATERIALS AND METHODS: A …

Alzheimer's disease (AD) is still being recognized today as an unmet medical need.
Currently, there is no cure and early preclinical diagnostic assay available for AD. Therefore …

Dementia represents a major problem of health and disability, with a relevant economic
impact on our society. Despite important advances in pathogenesis, diagnosis and …

Neurodegenerative diseases such as Alzheimer, Parkinson, amyotrophic lateral sclerosis,
and Huntington are incurable and debilitating conditions that result in progressive death of …

Increasing evidence suggests that inflammatory and immune components in brain are
important in Alzheimer's disease (AD) and anti-inflammatory and immunotherapeutic …

Chronic cerebral hypoperfusion is considered to be a pivotal contributing factor of cognitive
impairments that occur in vascular dementia and Alzheimer's disease, and ideal drug …

Patients with spinal cord injury (SCI) are permanently paralysed and anaesthetic below the
lesion. This morbidity is attributed to the deposition of a dense scar at the injury site, the …

Background Immunotherapy with monoclonal antibodies that target amyloid beta has been
under investigation as a treatment for patients with Alzheimer's disease (AD). The 3000 and …